"Pharmacokinetics of Next Generation Cyanide Antidote Sulfanegen in Rab" by Michael W. Stutelberg, Alexandre R. Monteil et al.
 

Title

Pharmacokinetics of Next Generation Cyanide Antidote Sulfanegen in Rabbits

Document Type

Article

Publication Date

5-2017

Abstract

Aim: Sulfanegen has been shown to be an effective next generation cyanide antidote in multiple animal studies. Sulfanegen detoxifies cyanide by acting as a sulfur donor, converting cyanide to thiocyanate through the enzyme 3-mercaptopyruvate (3-MP) sulfurtransferase. The current study was performed to determine the PK behavior of sulfanegen in rabbits and compare it to current US FDA-approved cyanide therapeutics. Methods: Plasma sulfanegen concentrations, as 3-MP (i.e., sulfanegen is a prodrug that converts to the active sulfur donor, 3-MP, upon administration), were monitored using LC–MS/MS following intramuscular administration of sulfanegen in rabbits. Results: Concentrations of 3-MP rapidly increased following sulfanegen administration, indicating rapid absorption and distribution of 3-MP throughout the body. Elimination of 3-MP was also relatively rapid; the calculated half-life was approximately 114 min. A one-compartment model with first-order distribution and elimination was used to describe the PK behavior of 3-MP. Conclusion: Overall, the PK characteristics of sulfanegen were found to be well suited for the rapid treatment of cyanide poisoning.

Publication Title

International Journal of Pharmacokinetics

Volume

2

Issue

2

First Page

105

Last Page

111

DOI of Published Version

10.4155/ipk-2016-0021

Link to Full Text

Plum Print visual indicator of research metrics
PlumX Metrics
  • Usage
    • Abstract Views: 28
see details

COinS